Search results for "ERYTHROPOIETIN"
showing 10 items of 113 documents
Anaemia in the critically ill patient: monitoring of erythropoietin therapy
2006
The Role of Erythropoietin in Neuroprotection: Therapeutic Perspectives
2007
Nervous system diseases are very complex conditions comprising a large variety of local and systemic responses. Several therapeutic agents interfering with all or in part the biochemical steps that ultimately cause neuronal death have been demonstrated to be neuroprotective in preclinical models. However, all the agents so far investigated have inexorably failed in the phase III trials carried out. A large body of evidence suggests that the hormone erythropoietin (EPO), besides its well-known hematopoietic action, exerts beneficial effects in the central nervous system. EPO's effect has been assessed in several experimental models of brain and spinal cord injury thus becoming a serious cand…
Emerging Therapeutic Strategies for Traumatic Spinal Cord Injury
2020
Spinal cord injury (SCI) is a debilitating neurologic condition with tremendous socioeconomic impact on affected individuals and the health care system. The treatment of SCI principally includes surgical treatment and marginal pharmacologic and rehabilitation therapies targeting secondary events with minor clinical improvements. This unsuccessful result mainly reflects the complexity of SCI pathophysiology and the diverse biochemical and physiologic changes that occur in the injured spinal cord. Once the nervous system is injured, cascades of cellular and molecular events are triggered at varying times. Although the cascade of tissue reactions and cell injury develops over a period of days …
Effects of Recombinant Human Erythropoietin (rHuEPO) on Tumor Control in Patients with Cancer-Induced Anemia
2005
It is well recognized that anemia-induced tumor hypoxia is associated with a reduced sensitivity of tumors to radiation and some forms of chemotherapy. Thus, the correction of lower hemoglobin (Hb) concentrations with recombinant human erythropoietin (rHuEPO) can play an essential role by improving tumor oxygenation. Based on evidence from a number of trials, treatment with rHuEPO will effectively ameliorate anemia and improve quality of life. However, one of the most essential prerequisites for achieving this benefit is the use of rHuEPO in agreement with the evidence-based ASCO/ASH-guidelines recommending a target Hb concentration of 12 g/dl (7.44 mmol/l).
Hypoxia and Aggressive Tumor Phenotype: Implications for Therapy and Prognosis
2008
Abstract Tumor hypoxia, mostly resulting from poor perfusion and anemia, is one of the key factors in inducing the development of cell clones with an aggressive and treatment-resistant phenotype that leads to rapid progression and poor prognosis. Studies in patients with solid tumors suggest that there is a range of hemoglobin (Hb) concentrations that is optimum for tumor oxygenation. When used to achieve an Hb level within this range, erythropoiesis-stimulating agents (ESAs) can be expected to increase tumor oxygenation, and this may favorably influence sensitivity to treatment as well as quality of life. There is no robust evidence that ESAs, when used as indicated, have a negative effect…
Erythropoietin: effects on life expectancy in patients with cancer-related anaemia
2006
ABSTRACTAnaemia is common in patients with cancer and has a detrimental impact on the quality of life. Anaemia has also been shown to reduce survival in patients with cancer. Tumour hypoxia resulting from the reduced oxygen carrying capacity of the blood in anaemic patients has been hypothesised to be a major contributor to this reduced survival. Several studies have shown that tumour hypoxia reduces the effectiveness of anticancer therapies including standard radiotherapy and some types of chemotherapy, and is associated with tumour progression. Moreover, preclinical data have demonstrated that erythropoietic protein therapy may delay tumour progression by improving tumour oxygenation. Mos…
When Neuroprotection Becomes a Potential Ally of High-Grade Glioma.
2019
Despite the use of multimodal treatment regimens, high-grade gliomas (HHGs) are tumors invariably associated with a poor prognosis. The median patient survival after diagnosis is approximately 1 year, through surgery/radiation and chemotherapy treatments.To date, traditional approaches fail to treat efficiently HHGs because surgery does not completely remove the tumor without damaging the brain, radiation therapy cannot be used beyond a certain threshold dose, and chemotherapy has shown limited efficacy and toxic effects. Notwithstanding many attempts at improving outcome using novel agents, the treatment of this disease has not improved in more than a decade. Although scientific and techno…
Erythropoietin to treat anaemia in patients with head and neck cancer
2004
based on the improvement of tumour oxygenation through direct effects (oxygen enhancement effect of radiotherapy) and indirect effects (counteraction of the adverse influence of tumour hypoxia on malignant progression), only increases in haemoglobin concentration that result in improvements in tumour oxygenation can be expected to have a favourable effect on prognosis. The haemoglobin concentration range leading to the highest tumour oxygen levels is most probably between 130 and 140 g/L, since this concentration represents an optimum in terms of the counteracting effects of increasing the blood’s oxygen-carrying capacity and rising viscous resistance to flow. At higher haemoglobin concentr…
Mast cells in canine mammary gland tumour: number, distribution and EPOR positivity.
2011
Erythropoietin (EPO)-mediated mitogenic and anti-apoptotic effects involve all the cells expressing functional receptors for EPO (EPOR), as demonstrated by in vitro and in vivo studies. EPO shows pleiotropic effects and acts as an endogenous mediator of adaptive tissue response to metabolic stress protecting tissues from different injuries. Recently, the EPO/EPOR complex has been identified in several neoplastic cell lines and solid tumours. In this study, the authors investigated the mast cells (MCs) number, distribution and their immunoreactivity for EPOR in normal, dysplastic and neoplastic canine mammary gland. The results showed that MCs were more numerous in displastic glands compared…